Emanuele Mazzola

Emanuele Mazzola

Auto-generated profile, based on publicly available information

Emanuele Mazzola

Dana-Farber Cancer Institute 3 Department of Biostatistics and Computational Biology Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
RKRobert Knoerl
Robert Knoerl
EMEmanuele Mazzola
Emanuele Mazzola
HWHeather Woods
Heather Woods
EBElizabeth Buchbinder
Elizabeth Buchbinder
LFLindsay Frazier
Lindsay Frazier
JLJennifer A. Ligibel
Jennifer A. Ligibel

1 January 2015 in Cancer Informatics
Verified
Journal Article
Open access
EMEmanuele Mazzola
Emanuele Mazzola
ABAmanda Blackford
Amanda Blackford
GPGiovanni Parmigiani
Giovanni Parmigiani
SBSwati Biswas
Swati Biswas
BRCAPRO is a widely used model for genetic risk prediction of breast cancer. It is a function within the R package BayesMendel and is used to calculate the probabilities of being a carrier of a deleterious mutation in one or both of the BRCA genes, as well as the probability of being affected with breast and ovarian cancer within a defined time window. Both predictions are based on information contained in the counselee's family history of cancer. During the last decade, BRCAPRO has undergone several rounds of successive refinements: the current version is part of release 2.1 of BayesMendel. In this review, we showcase some of the most notable features of the software resulting from these recent changes. We provide examples highlighting each feature, using artificial pedigrees motivated by complex clinical examples. We illustrate how BRCAPRO is a comprehensive software for genetic risk prediction with many useful features that allow users the flexibility to incorporate varying amounts of available information.

18 January 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CHCandace Lynn Haddox
Candace Lynn Haddox
MNMichael Jason Nathenson
Michael Jason Nathenson
EMEmanuele Mazzola
Emanuele Mazzola
JLJia-Ren Lin
Jia-Ren Lin
JBJoanna Baginska
Joanna Baginska
SGSuzanne George
Suzanne George
Purpose: Eribulin modulates the tumor-immune microenvironment via cGAS-STING signaling in preclinical models. This non-randomized phase II trial evaluated the combination of eribulin and pembrolizumab in patients with soft-tissue sarcomas (STS). Patients and Methods: Patients enrolled in one of three cohorts: leiomyosarcoma (LMS), liposarcomas (LPS), or other STS that may benefit from PD-1 inhibitors, including undifferentiated pleomorphic sarcoma (UPS). Eribulin was administered at 1.4 mg/m2 i.v. (days 1 and 8) with fixed-dose pembrolizumab 200 mg i.v. (day 1) of each 21-day cycle, until progression, unacceptable toxicity, or completion of 2 years of treatment. The primary endpoint was the 12-week progression-free survival rate (PFS-12) in each cohort. Secondary endpoints included the objective response rate, median PFS, safety profile, and overall survival (OS). Pretreatment and on-treatment blood specimens were evaluated in patients who achieved durable disease control (DDC) or progression within 12 weeks [early progression (EP)]. Multiplexed immunofluorescence was performed on archival LPS samples from patients with DDC or EP. Results: Fifty-seven patients enrolled (LMS, n = 19; LPS, n = 20; UPS/Other, n = 18). The PFS-12 was 36.8% (90% confidence interval: 22.5–60.4) for LMS, 69.6% (54.5–89.0) for LPS, and 52.6% (36.8–75.3) for UPS/Other cohorts. All 3 patients in the UPS/Other cohort with angiosarcoma achieved RECIST responses. Toxicity was manageable. Higher IFNα and IL4 serum levels were associated with clinical benefit. Immune aggregates expressing PD-1 and PD-L1 were observed in a patient that completed 2 years of treatment. Conclusions: The combination of eribulin and pembrolizumab demonstrated promising activity in LPS and angiosarcoma.

12 July 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
RDRachel S. Deming
Rachel S. Deming
EMEmanuele Mazzola
Emanuele Mazzola
JMJeanne MacDonald
Jeanne MacDonald
SMSimon Manning
Simon Manning
LBLeah Beight
Leah Beight
JWJoanne Wolfe
Joanne Wolfe

31 July 2014 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
EMEmanuele Mazzola
Emanuele Mazzola
JCJonathan Chipman
Jonathan Chipman
SCSu-Chun Cheng
Su-Chun Cheng
GPGiovanni Parmigiani
Giovanni Parmigiani
The recent release of version 2.0-8 of the BayesMendel package contains an updated BRCAPRO risk prediction model, which includes revised modeling of contralateral breast cancer (CBC) penetrance, provisions for pedigrees of mixed ethnicity and an adjustment for mastectomies among family members. We estimated penetrance functions for CBC by a combination of parametric survival modeling of literature data and deconvolution of SEER9 data. We then validated the resulting updated model of CBC in BRCAPRO by comparing it with the previous release (BayesMendel 2.0-7), using pedigrees from the Cancer Genetics Network (CGN) Model Validation Study. Version 2.0-8 of BRCAPRO discriminates BRCA1/BRCA2 carriers from noncarriers with similar accuracy compared with the previous version (increase in AUC, 0.0043), is slightly more precise in terms of the root-mean-square error (decrease in RMSE, 0.0108), and it significantly improves calibration (ratio of observed to expected events of 0.9765 in version 2.0-8, compared with 0.8910 in version 2.0-7). We recommend that the new version be used in clinical counseling, particularly in settings where families with CBC are common. Cancer Epidemiol Biomarkers Prev; 23(8); 1689–95. ©2014 AACR.

1 January 2022 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
DDDaniel Dolan
Daniel Dolan
SSScott J Swanson
Scott J Swanson
RGRitu Israel lahey Gill
Ritu Israel lahey Gill
DLDaniel N. Lee
Daniel N. Lee
EMEmanuele Mazzola
Emanuele Mazzola
AWAbby White
Abby White